Skip to main content
. Author manuscript; available in PMC: 2011 Mar 16.
Published in final edited form as: Oncogene. 2010 Jun 28;29(37):5193–5203. doi: 10.1038/onc.2010.257

Figure 6.

Figure 6

RNAi of HRG synergizes with HER2 TKI lapatinib. (a) 3D structures of MCF10A/HER2 cells expressing WT, EK or HR PI3K grown for 14 days on Matrigel in absence and presence of 1 μM lapatinib. b and c, MCF10A/HER2/HR (b) and HCC1954 (c) cells were transfected with control or HRG siRNAs and treated with 0.03 and 0.1 μM lapatinib, respectively. Cells numbers were measured on day 5. Each data point represents the mean ± SE of nine replicates. (d) pHER2Y1248, pHER3Y1289 and pAKTS473 in cells treated with 1 μM lapatinib and/or 250 nM BEZ by IB. (e) MCF10A/HER2/HR cells were treated with 1 μM lapatinib and/or 250nM BEZ for 6 days and cell numbers were counted. Each bar represents the mean ± SD of six replicates. *, p<0.05, paired t-test.